195 related articles for article (PubMed ID: 36354733)
1. HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.
Mais V; Fais ML; Peiretti M; Fanni D; Massa E; Carboni G; Fais G; Deo G; Angioni S
Curr Oncol; 2022 Nov; 29(11):8540-8555. PubMed ID: 36354733
[TBL] [Abstract][Full Text] [Related]
2. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.
Jiang SW; Chen H; Dowdy S; Fu A; Attewell J; Kalogera E; Drapkin R; Podratz K; Broaddus R; Li J
Int J Mol Sci; 2013 Nov; 14(11):22655-77. PubMed ID: 24252907
[TBL] [Abstract][Full Text] [Related]
3. Expression of HE4 in Endometrial Cancer and Its Clinical Significance.
Li X; Gao Y; Tan M; Zhuang H; Gao J; Hu Z; Wang H; Zhu L; Liu J; Lin B
Biomed Res Int; 2015; 2015():437468. PubMed ID: 26539494
[TBL] [Abstract][Full Text] [Related]
4. Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer.
Espiau Romera A; Coronado Martín PJ; Chóliz Ezquerro M; Cuesta Guardiola T; Adiego Calvo I; Baquedano Mainar L
Int J Gynaecol Obstet; 2021 Apr; 153(1):64-70. PubMed ID: 33156532
[TBL] [Abstract][Full Text] [Related]
5. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
6. A critical review on HE4 performance in endometrial cancer: where are we now?
Angioli R; Miranda A; Aloisi A; Montera R; Capriglione S; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2014 Feb; 35(2):881-7. PubMed ID: 24068567
[TBL] [Abstract][Full Text] [Related]
7. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.
Capriglione S; Plotti F; Miranda A; Ricciardi R; Scaletta G; Aloisi A; Guzzo F; Montera R; Angioli R
Tumour Biol; 2015 Jun; 36(6):4151-6. PubMed ID: 25577252
[TBL] [Abstract][Full Text] [Related]
8. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
9. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.
Deng L; Gao Y; Li X; Cai M; Wang H; Zhuang H; Tan M; Liu S; Hao Y; Lin B
J Exp Clin Cancer Res; 2015 Sep; 34(1):96. PubMed ID: 26362938
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum HE4 level in the management of endometrial cancer: A pilot study.
Rajadevan N; McNally O; Neesham D; Richards A; Naaman Y
Aust N Z J Obstet Gynaecol; 2021 Apr; 61(2):284-289. PubMed ID: 33528032
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Human Epididymis Protein4 (HE4) in Endometrial Lesions: Study in a Tertiary Care Centre.
Das S; Saha R; Das C; Deb M; Kamilya G
Indian J Surg Oncol; 2023 Jun; 14(2):428-433. PubMed ID: 37324288
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
14. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer.
Espiau Romera A; Cuesta Guardiola T; Benito Vielba M; De Bonrostro Torralba C; Coronado Martín PJ; Baquedano Mainar L
Int J Gynaecol Obstet; 2020 Jun; 149(3):265-268. PubMed ID: 32147821
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
16. Endometrial cancer: A systematic review of HE4, REM and REM-B.
Degez M; Caillon H; Chauviré-Drouard A; Leroy M; Lair D; Winer N; Thubert T; Dochez V
Clin Chim Acta; 2021 Apr; 515():27-36. PubMed ID: 33388311
[TBL] [Abstract][Full Text] [Related]
17. [The importance of HE4 in differential diagnosis of endometrial cancer].
Minář L; Klabenešová I; Jandáková E
Ceska Gynekol; 2015 Aug; 80(4):256-63. PubMed ID: 26265413
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.
Han LN; Han YW; Yan P
J Obstet Gynaecol Res; 2022 Sep; 48(9):2255-2269. PubMed ID: 35844088
[TBL] [Abstract][Full Text] [Related]
19. Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.
Chen Y; Chen Q; Liu Q; Gao F
Tumour Biol; 2016 Jun; 37(6):8359-65. PubMed ID: 26733162
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
J Obstet Gynaecol Res; 2015 Oct; 41(10):1644-52. PubMed ID: 26223178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
